RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced that it has received first place recognition at the 2012 Diagnostic Marketing Association (DxMA) Creative Communications Awards for the integrated print and online category for LipoScience’s NMR LipoProfile® test campaign.
The award was presented at the 2012 DxMA awards reception on April 25 in Chicago. The DxMA recognizes excellence in diagnostics marketing, advertising and promotional programming. LipoScience partnered with Motivation Mechanics, a Philadelphia-based marketing research and communications strategy firm, on the campaign.
“It is an honor to be recognized by the DxMA for our clinical communication initiatives,” said Mark Kirtland, Vice President, Marketing and Business Development at LipoScience. “The goal of our educational campaign continues to focus on increasing awareness of the NMR LipoProfile test and communicating the clinical value it can provide physicians and their patients in managing cardiovascular disease risk.”
“We are extremely proud of this industry award, which acknowledges the efforts of our marketing team to educate the broader physician community,” said Richard O. Brajer, President and Chief Executive Officer of LipoScience.
About the DxMA
The Diagnostic Marketing Association is a group of marketing and regulatory professionals that have spent their career in the diagnostics and device market segments. Its goal is to provide continued education and insight into the medical diagnostic industry. Its membership ranks reflect the sweeping spectrum of diagnostic marketing disciplines of leading diagnostic companies as well as service providers. For over 22 years the Dx Creative Communications Awards have honored the best of the best in diagnostics marketing, advertising and promotional programming.
About LipoScience, Inc.
LipoScience, Inc. is an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary technology platform based on nuclear magnetic resonance (NMR) technology. Our first diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 7 million NMR LipoProfile tests have been ordered. For further information on the Company, please visit www.liposcience.com and www.theparticletest.com.